This is a Single Ascending Dose Tolerance Study

A Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of SLV354 After Oral Dose Administration in Healthy Adult Male Subjects

This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance imaging (Part B)

The Part A of this study is a parallel design followed in a second part by a cross-over design

Inclusion Criteria

• BMI 18.0 to 28.0 kg/m2,
• systolic blood pressure 90-140 mmHg,
• diastolic blood pressure 50-90 mmHg,
• heart rate 50 100 beats/min (all inclusive),
• clinically normal safety ECG and laboratory results

Exclusion Criteria

• relevant disease,
• treated with SLV354 before